ライフサイエンスコーパス: JAK2

1 Cs expressing phosphorylated Janus kinase 2 (JAK2).

2 lved in mRNA processing as targets of mutant JAK2.

3 , we questioned whether TFEB is regulated by JAK2.

4 y consequence of mutated/hyperphosphorylated JAK2.

5 xpression in RAW 264.7 cells did not require JAK2.

6 y, which places CRY activity downstream from JAK2.

7 or STAT3 via gp130 and its downstream kinase JAK2.

8 thus eradicate cells harbouring mutations in JAK2.

9 6DelInsSer/Gln/Pro) within the JH2 domain of JAK2.

10 tudies have elucidated the metabolic role of JAK2, a key mediator downstream of various cytokines and

11 n was associated with increased TPO-mediated JAK2 activation and protein levels, and increased MPL re

12 We performed a systematic analysis of JAK2 activation requirements using structure-guided muta

13 ferences for pathogenic and cytokine-induced JAK2 activation to enable design of novel selective JAK

14 n regulating tumor-suppressive responses via JAK2 activation, but the underlying mechanisms are large

15 irst time the ability of A77 1726 to inhibit JAK2 activity and suggests that inhibition of JAK activi

16 JAK2 activity was inhibited using either curcumin, a nat

17 B treatment nor myeloid-specific deletion of JAK2 affected FPN1 expression.

18 ued by expression of a constitutively active Jak2 allele.

19 At two loci (JAK2 and A1CF), experimental analysis in mice showed lip

20 Pacritinib, which inhibits both JAK2 and FLT3, induced spleen responses with limited mye

21 f less than 20 nM, is <100 nM potent against JAK2 and HDAC11, and is selective for the JAK family aga

22 required for T cell differentiation, such as JAK2 and IL12RB2, are regulated by H3K27me3.

23 < 10(-7), including the associations between JAK2 and myeloproliferative disease, HOXB13 and cancer o

24 Endogenous JAK2 and phospho-JAK2 were rapidly K63-ubiquitinated upo

25 ACEE also reduced the levels of JAK2 and phosphorylated STAT3 in LLC cells.

26 formed cells, no synergy is observed between JAK2 and PI3-K inhibitors in inhibiting cytokine-indepen

27 This occurs independently from JAK2 and Rac signalling, but is required for full phosph

28 Intriguingly, JAK2 and RAS-mutations are mutually exclusive in leukemi

29 impaired by Gab2 deletion via regulation of Jak2 and signal transducer and activator of transcriptio

30 is good evidence for activation of the JAK1/JAK2 and signal transducer and activator of transcriptio

31 our results indicated that dual targeting of JAK2 and SMO resulted in synergistic suppression of brea

32 Moreover, an increase in phosphorylated JAK2 and STAT3 accompanied chemical induction of LTD and

33 n through activation of the tyrosine kinase; JAK2 and the lipid kinase phosphatidylinositide 3-kinase

34 s, they differentially use the Janus kinase (Jak2) and phosphatidylinositol 3-kinase (Pi3k) signaling

35 phenocopy BCR-ABL1 and alterations of CRLF2, JAK2, and EPOR that activate JAK/STAT signaling.

36 ing INCR1 decreases the expression of PD-L1, JAK2, and several other IFNgamma-stimulated genes.

37 -DLBCL, which shows higher levels of IL10RA, JAK2, and STAT3 but lower levels of BCL6 than GC-DLBCL a

38 A77 1726 inhibited JAK1, JAK2, and STAT3 tyrosine phosphorylation.

39 ivation of the Janus family kinases JAK1 and JAK2 are hallmarks of the final common pathway in this d

40 Our findings show that mutated FLT3-ITD and JAK2 augment ROS production and HR, shifting the cellula

41 We found that expression of mutant JAK2 augmented and subverted metabolic activity of MPN c

42 Furthermore, the PHB/JAK2 axis was found as a novel mechanism in the maintena

43 molecules that may regulate the activity of JAK2 by selective binding to the JAK2 pseudokinase domai

44 Somatic mutations in JAK2, CALR, and MPL have been described as drivers of th

45 ic mutations in the 3 driver genes, that is, JAK2, CALR, and MPL, represent major diagnostic criteria

46 s, which are largely defined by mutations in JAK2, CALR, or MPL In the B-cell lymphomas, detection of

47 egakaryocytic proliferation, and presence of JAK2, CALR, or MPL mutation are the main diagnostic crit

48 in and/or collagen fibrosis, and presence of JAK2, CALR, or MPL mutation.

49 a mutually exclusive manner in 1 of 3 genes: JAK2, CALR, or MPL The thrombopoietin receptor, MPL, is

50 tricted driver mutations, including those in JAK2, calreticulin (CALR), and myeloproliferative leukem

51 ll development and activation (PAX5, CDKN1B, JAK2, CARD11) and found a number of context-specific dep

52 Functionally, JAK2-catalyzed phosphorylation enabled CBP to bind with

53 JAK2 clinical mutations cause myeloproliferative neoplas

54 itutive signaling driven by mutated FLT3 and JAK2 confers interchromosomal homologous recombination (

55 lectively, our findings show that macrophage JAK2 deficiency improves systemic insulin sensitivity an

56 e, we investigated the phenotypic effects of JAK2 deficiency.

57 Finally, overexpression of TFEB in JAK2-deficient podocytes reversed lysosomal dysfunction

58 AK2/STAT3 dependent, while IL-17A was mostly JAK2 dependent.

59 tion, YBX1 inactivation induces apoptosis in JAK2-dependent mouse and primary human cells, causing re

60 The phosphorylation of STAT5B on the JAK2-dependent Y699 site is significantly reduced in the

61 Whether a competing JAK2 deubiquitination activity exists is unknown.

62 revealed that the associated Janus kinase 2 (JAK2) dimerizes through its pseudokinase domain.

63 re fundamental to the pathogenesis of mutant JAK2-driven myeloproliferative neoplasms (MPNs).

64 y effects on the neighboring genes PD-L1 and JAK2, enabling their expression.

65 ion causes splicing-dependent alterations of JAK2-ERK signalling and the maintenance of JAK2(V617F) m

66 presses JAK2-N542-E543del, the most frequent JAK2 exon 12 mutation found in PV patients.

67 In normal kidneys, JAK2 expression is limited to tubular epithelial and vas

68 ipients, which facilitated evaluation of the JAK2/FLT3 inhibitor pacritinib in vivo.

69 sence of JAK2V617F mutation, suggesting that JAK2-FOXO signaling has a different effect on progenitor

70 ts of cibinetide were dependent on CD131 and JAK2 functionality and were mediated via inhibition of N

71 ating these pathologies by sparing essential JAK2 functions.

72 In contrast, patients with FGFR1 and JAK2 fusion TK genes exhibit a more aggressive course an

73 and PDGFRB) in 14.1%, EPOR rearrangements or JAK2 fusions in 8.8%, alterations activating other JAK-S

74 rrow due to mutations in the Janus kinase 2 (JAK2) gene.

75 ing mutations in known driver genes (DNMT3A, JAK2, GNAS, TET2, and ASXL1), including 196 point mutati

76 Mice in which JAK2 had been deleted from podocytes exhibited an elevat

77 LNK abrogated JAK2 ubiquitination, extended JAK2 half-life, and enhanced JAK2 signaling and cell gro

78 The nonreceptor kinase Janus kinase 2 (JAK2) has garnered attention as a promising therapeutic

79 Other mutations in JAK2 have been identified in MPNs, most notably exon 12

80 ular mechanisms underlying the regulation of JAK2 have remained elusive.

81 emory CD8(+) T cells couples Janus kinase 2 (JAK2) hyperactivation to the phosphorylation of CREB-bin

82 tions activating the JAK-STAT pathway (JAK1, JAK2, IL7R) identified in 63 patients (50.8% of those wi

83 Importantly, inhibition of Jak2 impairs tyrosine 78 phosphorylation and tumor growt

84 Therefore, JAK2 in adipose tissue is epistatic to liver with regard

85 Here, we investigate the role of JAK2 in ADPKD using a murine model of ADPKD (Pkd1(nl/nl)

86 stimulation of the B-cell receptor activates JAK2 in CLL cells and the JAK2 inhibitor ruxolitinib imp

87 However, concomitant deletion of Jak2 in hepatocytes and adipocytes (JAK2LA) completely n

88 SF2 in CMML, ASXL1-SETBP1 in aCML, and SF3B1-JAK2 in MDS/MPN-RS-T).

89 reveal a novel signaling axis that regulates JAK2 in normal and malignant HSPCs and suggest new thera

90 vations highlight the homeostatic actions of JAK2 in podocytes and the importance of TFEB to autophag

91 y addresses the essential role of macrophage JAK2 in the pathogenesis to obesity-associated inflammat

92 nt of PDGFRA, PDGFRB, or FGFR1, or with PCM1-JAK2" In addition to myeloproliferative neoplasms (MPN),

93 ther members of the ErbB family and a slower JAK2 independent activation STAT5 through HER4.

94 hat FED exerted its effects through multiple JAK2-independent mechanisms.

95 pathway to NRG stimulation, while the slower JAK2-independent pathway is necessary for the late stage

96 satory ERK activation limits the efficacy of JAK2 inhibition and dual JAK/MEK inhibition provides an

97 dependent ERK signalling in combination with JAK2 inhibition could thus eradicate cells harbouring mu

98 JAK2 inhibition ex vivo inhibited MEK/ERK signaling, sug

99 erent stimulation, and this was prevented by JAK2 inhibition in the OFC.

100 activated kinase that remains activated upon JAK2 inhibition in vivo, and PDGF-AA/PDGF-BB production

101 JAK2 inhibition led to significantly reduced tyrosine ph

102 nd JAK2/STAT1-dependent manner, and specific JAK2 inhibition prevented PD-L1 upregulation in tumor ce

103 Type I and II JAK2 inhibition suppressed MEK/ERK activation in MPN cel

104 ut was prevented by dual IL6/LIF blockade or JAK2 inhibition.

105 lated protein Arc, and this was prevented by JAK2 inhibition.

106 her curcumin, a natural compound with strong JAK2 inhibitor activity, or Tofacitinib, a clinically us

107 The JAK2 inhibitor AG490 given systemically or into the OFC

108 The JAK1/JAK2 inhibitor AZD1480 blocked the effect of cytokines o

109 esistant tumors, and treatment with the JAK1/JAK2 inhibitor CYT387 reduced progression of chemoresist

110 The only approved JAK2 inhibitor for myelofibrosis is the dual JAK1 and JA

111 receptor activates JAK2 in CLL cells and the JAK2 inhibitor ruxolitinib improves symptoms in patients

112 A-MSC is abrogated by dual blockade with the JAK2 inhibitor ruxolitinib to a much greater extent than

113 rden, after the introduction of the JAK1 and JAK2 inhibitor ruxolitinib.

114 , IL-2 and IL-4 that is reverted by the JAK1/JAK2 inhibitor ruxolitinib.

115 rt and efficient commercial synthesis of the JAK2 inhibitor, a complex pyrrolopyridine, BMS-911543, i

116 Baricitinib, a clinically approved JAK1/JAK2 inhibitor, is currently being investigated in COVID

117 bitor for myelofibrosis is the dual JAK1 and JAK2 inhibitor, ruxolitinib.

118 tudy, ruxolitinib, a Janus kinase (JAK)1 and JAK2 inhibitor, was superior to best available therapy a

119 olitinib, a selective Janus kinase (JAK1 and JAK2) inhibitor, showed potential efficacy in patients w

120 Herein, we show that novel combinations of JAK2 inhibitors (ruxolitinib and pacritinib) with SMO in

121 Janus kinase (JAK) 1/JAK2 inhibitors are in development or clinical use for i

122 oped as targeted therapies for MPNs, current JAK2 inhibitors do not preferentially target MPN stem ce

123 ork for repurposing clinically approved JAK1/JAK2 inhibitors for type 1 diabetes.

124 Several other JAK2 inhibitors have entered clinical testing, but none

125 of which could successfully be combined with JAK2 inhibitors in the future.

126 The place of JAK2 inhibitors in the treatment of diffuse large B-cell

127 However, the therapeutic efficacy of current JAK2 inhibitors is limited.

128 mphoma has not been defined; we suggest that JAK2 inhibitors might be most effective in poor prognosi

129 Although JAK2 inhibitors provide substantial clinical benefit, th

130 If approved, less myelosuppressive JAK2 inhibitors such as pacritinib or NS-018 could prove

131 ly or best available therapy (BAT) excluding JAK2 inhibitors until disease progression or unacceptabl

132 In addition, new JAK2 inhibitors with the potential for less myelosuppres

133 e autophosphorylation of wild-type and V617F JAK2 is also contrasted.

134 , being ubiquitously expressed in the adult, JAK2 is also likely to be necessary for normal organ fun

135 The JAK gene JAK2 is frequently mutated in the ageing haematopoietic

136 By contrast, in kidneys of mice with ADPKD, JAK2 is higher in cyst-lining cells when compared to nor

137 We previously found that JAK2 is promptly ubiquitinated upon cytokine stimulation

138 in combination with constitutionally active JAK2 is sufficient to activate wtRAS.

139 Janus kinase 2 (JAK2) is a central kinase in hematopoietic stem/progenit

140 utation in the JH2 domain of Janus kinase 2 (JAK2) is an oncogenic driver in several myeloproliferati

141 and almost completely abrogate heteromeric (JAK2-JAK1) IFN-gamma signaling, potentially by disruptin

142 ereas JH2 alphaC mutations reduce homomeric (JAK2-JAK2) erythropoietin signaling and almost completel

143 hormone (GH) signaling through disruption of Jak2 (JAK2L) leads to fatty liver.

144 At the same time, phosphorylation of JAK2 kinase was not reduced upon Cry deficiency, which p

145 is regulated through growth hormone-induced, JAK2 kinase-mediated phosphorylation of transcriptional

146 In immortalized mouse podocytes, JAK2 knockdown decreased TFEB promoter activity, express

147 toneal macrophages from M-JAK2(-/-) mice and Jak2 knockdown in macrophage cell line RAW 264.7 also sh

148 ion of several of the genes downregulated by JAK2 knockdown, we questioned whether TFEB is regulated

149 -fat diet (HFD) feeding, macrophage-specific JAK2 knockout (M-JAK2(-/-)) mice gained less body weight

150 repression of the oncogenic kinases FLT3 and JAK2, leading to enhanced ERK and STAT3 signaling.

151 tol 3-kinase (Pi3k) signaling pathways, with Jak2 mainly relaying the proproliferation signaling, whe

152 in the interstitium, suggesting that ectopic JAK2 may contribute to ADPKD.

153 The observed JAK2-mediated epigenetic changes in histone modification

154 MMB is not mediated by direct inhibition of JAK2-mediated ferroportin (FPN1) degradation, because ne

155 tyrosine 78 of Atoh1 is phosphorylated by a Jak2-mediated pathway only in tumor-initiating cells and

156 nt as the wild-type ligand, there is reduced JAK2-mediated phosphorylation of select downstream targe

157 Taken together, inhibiting Jak2-mediated tyrosine 78 phosphorylation could provide

158 t compared to wildtype littermate control (M-JAK2(+/+)) mice and were protected from HFD-induced syst

159 Peritoneal macrophages from M-JAK2(-/-) mice and Jak2 knockdown in macrophage cell lin

160 and chemokines in liver and VAT of HFD-fed M-JAK2(-/-) mice.

161 n visceral adipose tissue (VAT) of HFD-fed M-JAK2(-/-) mice.

162 eeding, macrophage-specific JAK2 knockout (M-JAK2(-/-)) mice gained less body weight compared to wild

163 tor and pJAK2/JAK2, thus enhancing activated JAK2/MPL at the cell membrane.

164 lyses identified numerous metabolic nodes in JAK2-mutant hematopoietic stem and progenitor cells that

165 Oncogenic receptor and hyperactive JAK2 mutants promoted ligand-independent dimerization, h

166 xed effects on the overall disease burden of JAK2-mutated clones(6,7), prompting us to investigate th

167 PV shares the same JAK2 mutation as essential thrombocytosis and primary my

168 AK2V617F mouse models is the presence of the JAK2 mutation in all rather than in a few hematopoietic

169 Within the CRLF2(+) group, JAK2 mutation was associated with inferior outcomes.

170 Specifically, the predominant JAK2 mutation, V617F, is the most sensitive to structura

171 tin production, bone marrow panmyelosis, and JAK2 mutation.

172 ith shorter survival than was the absence of JAK2 mutations (P=0.001), owing to a high risk of death

173 The identification of JAK2 mutations as disease-initiating in myeloproliferati

174 JAK2 mutations constitutively activate downstream signal

175 significantly higher prevalence of PTPRT and JAK2 mutations in lung adenocarcinomas among African Ame

176 a high risk of relapse, and the presence of JAK2 mutations was associated with shorter survival than

177 d by high frequency of CRLF2-rearrangements, JAK2-mutations, or RAS-pathway mutations.

178 We generated a mouse model that expresses JAK2-N542-E543del, the most frequent JAK2 exon 12 mutati

179 Mutations in Janus kinase-2 (JAK2) occur in approximately 50% of patients.

180 individual roles of hepatocyte and adipocyte Jak2 on whole-body and tissue insulin sensitivity and li

181 ibiting the upstream Janus kinase (JAK) 1 or JAK2 or by STAT3 knockdown was found to increase SOX11 e

182 ted TRAP(+) OCs from 16 MF patients harbored JAK2 or calreticulin (CALR) mutations, confirming MF OCs

183 rrangements (51%), ABL class fusions (9.8%), JAK2 or EPOR rearrangements (12.4%), other JAK-STAT sequ

184 ype I interferon family, where it pairs with JAK2 or JAK1, respectively.

185 The discovery of mutations in JAK2 over a decade ago heralded a new age for patient ca

186 JAK2 overexpression enhanced H5N1 virus replication and

187 variants are in LD and affect expression of JAK2 (p 0.005 to 0.013), RCL1 (p 8.17E-13 to 2.98E-11) a

188 ), abnormally activate the cytokine receptor/JAK2 pathway and their downstream effectors, more partic

189 Treatments using imatinib and JAK2 pathway inhibitors can be effective on osteoscleros

190 CIC stress decreased JAK2 phosphorylation in the OFC, and ketamine restored p

191 ve shown that Janus kinases (JAK), JAK1, and JAK2, play an important role in IAV replication.

192 ed (CBL(mut) ) leukemias exhibited increased JAK2 protein levels and signaling and were hypersensitiv

193 activity of JAK2 by selective binding to the JAK2 pseudokinase domain, JH2.

194 ted the efficacy and safety of fedratinib, a JAK2-selective inhibitor, in patients with ruxolitinib-r

195 1, a post-translationally modified target of JAK2, sensitizes cells that persist despite treatment wi

196 ether, our results indicate that blockade of JAK2 shows promise as a novel therapeutic target in ADPK

197 cell lines with PRL activated signaling via JAK2-signal transducer and activator of transcription 3

198 pathways, one of the most notable being the JAK2/signal transducer and activator of transcription 5

199 ation, extended JAK2 half-life, and enhanced JAK2 signaling and cell growth in human cell lines as we

200 Deregulated JAK2 signaling has emerged as the central phenotypic dri

201 nating the regulation of both cell cycle and Jak2 signaling in HSCs.

202 Constitutive JAK2 signaling is central to myeloproliferative neoplasm

203 2 inhibitor, because erythropoietin-mediated JAK2 signaling is essential for erythropoiesis.

204 However, hepatocyte autonomous JAK2 signaling regulates liver lipid deposition under co

205 ays revealed that the downstream mediator of JAK2 signaling STAT1 binds to the TFEB promoter.

206 nsactivation of Socs3, a potent inhibitor of Jak2 signaling, in cycling HSCs.

207 rough dampening thrombopoietin (TPO)-induced JAK2 signaling.

208 attenuates HSC expansion through control of JAK2 signaling.

209 al activity, and is independent of canonical Jak2 signaling.

210 ely regulating thrombopoietin (Tpo)-mediated Jak2 signaling.

211 c drugs as agents that decreased PRL-induced JAK2 signaling; incubation of pancreatic cancer cells wi

212 y cytokine receptor-mediated Janus kinase 2 (JAK2) signaling.

213 k demonstrates how various tissues integrate JAK2 signals to regulate insulin/glucose and lipid metab

214 In cultured podocytes, knockdown of JAK2 similarly impaired autophagy and led to downregulat

215 Overall, we identified the JAK2 SNP rs56118985 to be significantly associated with

216 pathway by which K63-ubiquitination promotes JAK2 stability and activation in a proteasome-independen

217 L) family E3 ubiquitin ligases down-regulate JAK2 stability and signaling via the adaptor protein LNK

218 g of the incoming capsid and depended on the JAK2/STAT1 pathway.

219 ted production of H2O2 was shown to activate JAK2/STAT1 signaling, increase production of IL-1beta vi

220 PD-L1 expression was induced in an EGFR- and JAK2/STAT1-dependent manner, and specific JAK2 inhibitio

221 we determined whether novel combinations of JAK2-STAT3 and SMO-GLI1/tGLI1 inhibitors synergistically

222 tors of PI3K-AKT-NF-kappaB, IKK-NF-kappaB or JAK2-STAT3 pathways killed surviving GBM cells in both 2

223 tions and mutations inactivating SWI-SNF and JAK2-STAT3 pathways.

224 lves the activation of alpha7nAChR-dependent JAK2-STAT3 signaling pathway.

225 tion, as monitored by Ki67 and activation of JAK2-STAT3 signaling.

226 Further, Il-6 reinforced Jak2/Stat3 activation in SCPs and SCs.

227 implanted neuroblastoma cells, inhibition of JAK2/STAT3 and MEK/ERK/1/2 by ruxolitinib and trametinib

228 ed mice was dependent on the coactivation of JAK2/STAT3 and MEK/ERK1/2 in neuroblastoma cells.

229 Blockade of JAK2/STAT3 and TGF-beta signaling by specific inhibitors

230 Previously, we reported that the GM-CSF/JAK2/STAT3 axis drives liver-associated MDSC (L-MDSC) pr

231 Specifically, IL-22 production was TYK2/JAK2/STAT3 dependent, while IL-17A was mostly JAK2 depen

232 We then tested the role of JAK2/STAT3 in ketamine-induced plasticity in the OFC.

233 F-beta signaling inhibitor - SB431542 and/or JAK2/STAT3 inhibitor - JSI-124.

234 in receptor signaling inhibition by AG490, a JAK2/STAT3 inhibitor.

235 When considered along with upregulated Jak2/Stat3 pathways and cell proliferation, our data sup

236 We have shown that activating JAK2/STAT3 signaling in the OFC rescued the CIC stress-i

237 ss-induced reversal learning deficit, and if JAK2/STAT3 signaling is involved in this effect.

238 These results suggest that the JAK2/STAT3 signaling pathway is a novel mechanism by whi

239 Moreover, we examined the activity of jak2/stat3 signaling pathways and Adamts1, which are cri

240 study demontrated that the TGF-beta and IL-6/JAK2/STAT3 signaling pathways form a positive feedback s

241 K3R1 loss activates AKT and p110-independent JAK2/STAT3 signaling through inducing changes in the pho

242 w that FLLL32, a small molecule inhibitor of JAK2/STAT3 signaling, reduces neurofibroma growth in mic

243 ibition on AKT and promoting the assembly of JAK2/STAT3 signalosome, respectively.

244 gamma) signaling and its downstream effector Jak2/Stat3, which are required for HSC formation, are ma

245 cer cells vulnerable to inhibition of AKT or JAK2/STAT3.

246 crucial modifications to the canonical HER4-JAK2-STAT5 pathway based on literature findings.

247 cerning its activation of anti-proliferative JAK2-STAT5 pathway when stimulated by ligand Neuregulin

248 transducer and activator of transcription-5 (JAK2-STAT5) or phosphoinositide 3-kinase-Akt (PI3K-Akt)

249 ms of RANKL through metalloproteases and the JAK2/STAT5 pathway, and it helps in restoring the decrea

250 3 increases membrane RANKL by activating the JAK2/STAT5 pathway.

251 and thapsigargin, through activation of the JAK2/STAT5 pathway.

252 via its cognate receptor and the downstream JAK2-STAT5a signalling pathway.

253 addition to inducing NF-kappaB, LTA promotes JAK2/STAT6 signaling.

254 in referred to as JAK2ex13InDel) deregulates JAK2 through a mechanism similar to JAK2V617F, activates

255 sociation between the MPL receptor and pJAK2/JAK2, thus enhancing activated JAK2/MPL at the cell memb

256 ors in patients with diseases with unmutated JAK2, thus providing new insights into the development o

257 We discover that PD-L1 and JAK2 transcripts are negatively regulated by binding to

258 (gene of ST2), Ifng, Csf2, Stat5, Batf, and Jak2 Transplanting donor ST2(-/-) Tcons with WT or ST2(-

259 This increase in JAK2 ubiquitination after BRISC knockdown was associated

260 that depletion of CBL/CBL-B or LNK abrogated JAK2 ubiquitination, extended JAK2 half-life, and enhanc

261 We characterize inhibitory strategies for JAK2 V617F and assess their effect on physiologic signal

262 Suburban Population Study were screened for JAK2 V617F and CALR by droplet digital polymerase chain

263 The JAK2 V617F and calreticulin mutations (CALR) are frequen

264 tive myeloproliferative neoplasms (MPNs) and JAK2 V617F clonal hematopoiesis in the general populatio

265 We discuss how strategies aiming to inhibit JAK2 V617F could be used for identifying inhibitors of I

266 JAK2 V617F has been detected in the general population,

267 The JH2 alphaC region, which is required for JAK2 V617F hyperactivation, is crucial for relaying cyto

268 also assessed the effect of several specific JAK2 V617F inhibitory mutations on receptor dimerization

269 Like other JAK2 V617F inhibitory mutations, A598F decreased oncogen

270 The mutant JAK2 V617F is the most common molecular event associated

271 se agents is not restricted to patients with JAK2 V617F or exon 12 mutations.

272 Thus, we aimed to determine the CALR and JAK2 V617F population prevalence and assess the biochemi

273 Of 645 participants, 613 were JAK2 V617F positive, and 32 were CALR positive, correspo

274 JAK2 V617F positives with and without MPN presented elev

275 a novel population prevalence of CALR and a JAK2 V617F prevalence that is 3 to 30 times higher compa

276 Thirteen patients with JAK2 V617F(+) PV/ET were enrolled, and 12 (PV, n = 11; E

277 Approximately 6% and 14% of JAK2 V617F- essential thrombocythemia and primary myelof

278 spared cytokine activation while preventing JAK2 V617F-promoted erythropoietin receptor dimerization

279 neoplasms (MPNs) harbor the acquired somatic JAK2 (V617F) mutation.

280 eta1) and Cxcl12 pathways in mice expressing Jak2(V617F) In addition, expression of Hmga2 causes upre

281 ate that expression of Hmga2 cooperates with Jak2(V617F) in the pathogenesis of MF.

282 oiesis, we transduced bone marrow cells from Jak2(V617F) knockin mice with lentivirus expressing Hmga

283 f JAK2-ERK signalling and the maintenance of JAK2(V617F) malignant clones.

284 ted the development of MF in mice expressing Jak2(V617F) Mechanistically, the data show that expressi

285 tion and proliferation in the bone marrow of Jak2(V617F) mice, whereas TGF-beta1 or Cxcl12 stimulatio

286 oxyurea was highly effective in vivo against JAK2(V617F)(+) murine MPN-like disease and also against

287 (+) murine MPN-like disease and also against JAK2(V617F)(+), CALR(del52)(+), and MPL(W515L)(+) primar

288 s in the hemopoietic stem cell, most notably JAK2(V617F), CALR, and MPL.

289 We show here that cell lines expressing JAK2(V617F), MPL(W515L), or CALR(del52) accumulated reac

290 loproliferative neoplasms (MPNs) often carry JAK2(V617F), MPL(W515L), or CALR(del52) mutations.

291 e was associated with cooperative effects of JAK2-V617F and Hippo kinase inactivation on innate immun

292 Furthermore, EndMT is an early event in a JAK2-V617F knock-in mouse model of primary myelofibrosis

293 In a JAK2-V617F model, heterozygous Hippo kinase inactivation

294 errantly elevated IL-1beta production in the JAK2-V617F MPN model.

295 ive polymerase chain reaction (PCR) test for JAK2/V617F was negative.

296 5 (71%) of 35 molecular responders (with the JAK2 Val617Phe mutation) have maintained some response d

297 TYK2 potency and selectivity over off-target JAK2 was established.

298 Mutations in DNMT3A, TET2, ASXL1, and JAK2 were each individually associated with coronary hea

299 Endogenous JAK2 and phospho-JAK2 were rapidly K63-ubiquitinated upon TPO stimulation

300 way (IL12B, IL12RB2, TYK2, IFNGR1, JAK1, and JAK2) were hypermethylated in patients with TB.